Valuation: Acadia Pharmaceuticals Inc.

Market Cap 304.01Cr 276.89Cr 255.14Cr 232.08Cr 435.39Cr 28TCr 457.59Cr 3.11TCr 1.23TCr 15TCr 1.14TCr 1.12TCr 48TCr P/E 2026 *
22.1x
P/E 2027 * 17.2x
Enterprise Value 203.98Cr 185.79Cr 171.19Cr 155.72Cr 292.14Cr 19TCr 307.04Cr 2.08TCr 828.12Cr 10TCr 765.35Cr 749.21Cr 32TCr EV / Sales 2026 *
1.59x
EV / Sales 2027 * 1.24x
Free-Float
99.67%
Yield 2026 *
-
Yield 2027 * -
1 day-2.73%
1 week-5.68%
Current month-16.90%
1 month-13.59%
3 months-43.36%
6 months-16.46%
Current year-35.94%
1 week 17.05
Extreme 17.05
19.44
1 month 15.86
Extreme 15.855
22.63
Current year 15.86
Extreme 15.855
30.96
1 year 15.86
Extreme 15.855
30.96
3 years 13.4
Extreme 13.4
32.59
5 years 12.24
Extreme 12.24
33.99
10 years 12.24
Extreme 12.24
58.72
Manager TitleAgeSince
Chief Executive Officer 55 20/09/2024
Director of Finance/CFO 52 10/09/2021
Chief Tech/Sci/R&D Officer - 04/08/2025
Director TitleAgeSince
Director/Board Member 68 01/05/2008
Chairman 55 10/06/2016
Director/Board Member 73 25/11/2015
Date Insider Type Main position Quantity % Market Cap. Importance
30/10/26 Sell

Chief Financial Officer

-3,321 0.0019%
06/08/26 Exercice

Chief Financial Officer

42,876 0.0250%
30/07/26 Sell

Chief Technology Officer

-16,558 0.0097%
Change 5-day change 1-year change 3-year change Capi.($)
-2.73%-5.68%-25.93%-25.09% 304.01Cr
-2.49%-6.35%+51.07%+64.95% 6.54TCr
-0.63%-3.81%+6.95%+88.55% 5.89TCr
-2.37%-2.22%+22.96%+83.44% 5.52TCr
-2.19%-6.02%+10.50%+109.19% 4.57TCr
-1.89%-9.33%+13.03%+20.04% 4.13TCr
-0.93%+1.67%+20.83%+45.03% 3.68TCr
+1.11%-8.59%+128.56%+655.74% 3.45TCr
-0.80%-1.73%+75.29%+56.47% 3.25TCr
-2.17%+19.70%-30.57%+469.42% 3.17TCr
Average -1.48%-0.89%+27.27%+156.77% 4TCr
Weighted average by Cap. -1.46%-1.29%+31.19%+150.09%

Financials

2026 *2027 *
Net sales 128.1Cr 116.67Cr 107.51Cr 98Cr 183.46Cr 12TCr 192.81Cr 1.31TCr 520.03Cr 6.48TCr 480.62Cr 470.49Cr 20TCr 145.36Cr 132.39Cr 121.99Cr 110.97Cr 208.18Cr 13TCr 218.8Cr 1.48TCr 590.12Cr 7.35TCr 545.39Cr 533.89Cr 23TCr
Net income 14Cr 12Cr 11Cr 10Cr 20Cr 1.26TCr 21Cr 139.32Cr 55Cr 689.88Cr 51Cr 50Cr 2.17TCr 17Cr 16Cr 15Cr 13Cr 25Cr 1.62TCr 26Cr 178.47Cr 71Cr 883.74Cr 66Cr 64Cr 2.77TCr
Net Debt -100.02Cr -91Cr -84Cr -76Cr -143.25Cr -9.26TCr -150.55Cr -1.02TCr -406.06Cr -5.06TCr -375.28Cr -367.37Cr -16TCr -123.39Cr -112.38Cr -103.55Cr -94Cr -176.72Cr -11TCr -185.73Cr -1.26TCr -500.92Cr -6.24TCr -462.96Cr -453.2Cr -20TCr
Projected Income Statement - Annual - Acadia Pharmaceuticals Inc.
Logo Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.
Employees
797
Date Price Change Volume
21/26/21 $17.11 -2.73% 19,03,306
19/26/19 $17.59 -1.35% 14,50,822
18/26/18 $17.83 -2.67% 18,95,605
17/26/17 $18.32 -1.87% 15,35,422
16/26/16 $18.67 -0.43% 21,16,859
Trader
Investor
Global
Quality
ESG MSCI
B
MarketScreener Ratings - Acadia Pharmaceuticals Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
17.59USD
Average target price
30.21USD
Spread / Average Target
+71.75%
  1. Stock Market
  2. Stocks
  3. ACAD Stock